Asset
Sonrotoclax
BeOne Medicines Ltd. American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (18)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04973605 | phase1_2 | recruiting | 2021-09-16 | 2026-11-01 | BeOne Medicines | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma |
| NCT04771130 | phase1_2 | recruiting | 2021-05-24 | 2028-02-08 | BeOne Medicines | A Study of BGB-11417 in Participants With Myeloid Malignancies |
| NCT07770698 | phase1_2 | not_yet_recruiting | 2026-10-01 | 2030-04-30 | BeOne Medicines | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia |
| NCT06543043 | phase1 | completed | 2024-08-19 | 2024-10-08 | BeiGene | A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers |
| NCT05952037 | phase2 | active_not_recruiting | 2023-10-23 | 2026-09-22 | BeOne Medicines | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 220711 | NDA | BEONE MEDICINES USA INC |
Marketed products (4)
- BEQALZI
- BEQALZI
- BEQALZI
- BEQALZI